Surgify Medical, developer of Surgify Halo technology, has successfully raised €7 million (USD $7.9 million) in Series A funding.
Building on a successful Nordic market launch, the company will expand its operations in the EU and the United States, where key hospitals have already started adopting Surgify’s technology.
Surgify Halo cuts bone while providing protective capabilities against incidental injuries to soft tissues such as central nervous system structures, blood vessels and nerves. The technology provides effective bone resection in combination with a soft tissue protection feature for enhanced safety and precision in surgical procedures. Surgify Halo is MDR- and FDA-cleared.
Conventional surgical drills spin tens of thousands of times per minute and can be dangerous if they come into contact with critical soft tissue. At worst, such soft tissue damage can result in severe injury to the patient. Soft tissue injuries are considered a highly relevant surgical complication in many types of head, neck and spine procedures involving bone resection.
The funding round was led by ZEISS Ventures, the corporate venture arm of the Carl Zeiss Group, with participation from the European Innovation Council Fund (EIC Fund). Surgify’s existing investors, including Lednil and Cascara Ventures, also participated in the financing.
Surgify Medical, developer of Surgify Halo technology, has successfully raised €7 million (USD $7.9 million) in Series A funding.
Building on a successful Nordic market launch, the company will expand its operations in the EU and the United States, where key hospitals have already started adopting Surgify's technology.
Surgify Halo cuts...
Surgify Medical, developer of Surgify Halo technology, has successfully raised €7 million (USD $7.9 million) in Series A funding.
Building on a successful Nordic market launch, the company will expand its operations in the EU and the United States, where key hospitals have already started adopting Surgify’s technology.
Surgify Halo cuts bone while providing protective capabilities against incidental injuries to soft tissues such as central nervous system structures, blood vessels and nerves. The technology provides effective bone resection in combination with a soft tissue protection feature for enhanced safety and precision in surgical procedures. Surgify Halo is MDR- and FDA-cleared.
Conventional surgical drills spin tens of thousands of times per minute and can be dangerous if they come into contact with critical soft tissue. At worst, such soft tissue damage can result in severe injury to the patient. Soft tissue injuries are considered a highly relevant surgical complication in many types of head, neck and spine procedures involving bone resection.
The funding round was led by ZEISS Ventures, the corporate venture arm of the Carl Zeiss Group, with participation from the European Innovation Council Fund (EIC Fund). Surgify’s existing investors, including Lednil and Cascara Ventures, also participated in the financing.
Copy to clipboard 
